Twelve-month outcome of pretreated immunodeficiency virus 1-infected patients receiving triple antiretroviral therapy including dolutegravir in Bouaké (Côte D'Ivoire) from 2020 to 2021

Abstract

Objective: to describe the 12-month outcome of HIV-1-infected patients receiving dolutegravir.

Methodology: This was a cross-sectional study conducted over 18 months, including the records of HIV-1 positive patients, pre-treated with first-line triple antiretroviral therapy, in whom the 3rd agent Efavirenz was replaced by dolutegravir. Sociodemographic, clinical and immunovirological parameters after 12 months of switching were analyzed using Epi info 7.2.6 software.

Results: A total of 214 files were analyzed. The median age was 53 [47-59] and the sex ratio 0.9. Patients had been pre-treated for at least 5 years in 56.5% of cases. After 12 months on dolutegravir, no opportunistic infections or serious adverse events were reported. A mean weight gain of 2.06kg ± 4.3 at 6 months and 3.02kg ± 5.47 at 12 months of treatment was observed in each patient, irrespective of age, sex, CD4 count, age of infection or duration of initial treatment. In terms of immunology, the proportion of patients with CD4+ ≥500 elts/mm3 increased (54.2% versus 66.2%), with a significant association with dolutegravir (p=0.010). All patients (100%) were virally suppressed or undetectable at 6 and 12 months.

Conclusion: Dolutegravir showed efficacy and good clinical tolerability at 12 months. However, early weight gain was noted and needs to be monitored.